1. Home
  2. FUND vs IMMX Comparison

FUND vs IMMX Comparison

Compare FUND & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$9.86

Market Cap

259.7M

Sector

Finance

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$7.17

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUND
IMMX
Founded
1988
2014
Country
Canada
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.7M
306.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FUND
IMMX
Price
$9.86
$7.17
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.00
AVG Volume (30 Days)
32.5K
936.9K
Earning Date
01-01-0001
03-24-2026
Dividend Yield
6.64%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.75
$1.34
52 Week High
$8.47
$7.73

Technical Indicators

Market Signals
Indicator
FUND
IMMX
Relative Strength Index (RSI) 63.82 67.89
Support Level $9.41 $6.02
Resistance Level $9.96 $7.04
Average True Range (ATR) 0.15 0.58
MACD 0.01 0.12
Stochastic Oscillator 64.70 97.16

Price Performance

Historical Comparison
FUND
IMMX

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: